BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
Phase 4
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT01810666
A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation
Phase 4
Completed
- Conditions
- Constipation
- Interventions
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 97
- Registration Number
- NCT01810653
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
Phase 2
Completed
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1066
- Registration Number
- NCT01807221
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 113
- Registration Number
- NCT01805544
Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 411
- Registration Number
- NCT01805531
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2101
- Registration Number
- NCT01800006
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Phase 3
Completed
- Conditions
- Pneumonia, Bacterial
- Interventions
- Drug: Amikacin Inhalation Solution (BAY41-6551)Drug: Aerosolized Placebo
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 725
- Registration Number
- NCT01799993
Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases
Phase 1
Completed
- Conditions
- Neoplasm Metastasis
- Interventions
- Radiation: Radium-223 dichloride (BAY88-8223)
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 31
- Registration Number
- NCT01798108
- Locations
- πΈπͺ
Karolinska University Hospital, Stockholm, Sweden
π³π΄University Hospital of North Norway, Tromsoe, Norway
π³π΄The Norwegian Radium Hospital, Oslo, Norway
Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea
Completed
- Conditions
- Contraception
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027)
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 757
- Registration Number
- NCT01797809
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
Phase 4
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Procedure: Several diagnostic procedures
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 278
- Registration Number
- NCT01795872
Β© Copyright 2025. All Rights Reserved by MedPath